Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study
| Autor: | Sofia Pappa, Arturas Kalniunas, Hitendra Sharma, Ali Raza-Syed, Manzar Kamal, Fintan Larkin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Psychopharmacology, Vol 12 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2045-1261 20451253 |
| DOI: | 10.1177/20451253221132087 |
| Popis: | Background: Cariprazine, a novel antipsychotic drug, is a partial agonist of dopamine D2/D3 receptors with preferential binding to the D3 receptor. There has been an increasing interest in cariprazine augmentation to clozapine; however, the evidence thus far has been only limited to case reports and case series. Objectives: To evaluate the efficacy and safety of the augmentation of clozapine with cariprazine in patients with sub-optimal treatment response. Methods: Demographic and clinical information of the study population were collected from the electronic records and PANSS scale administered at baseline and 3 months. Tolerability and discontinuation reasons where applicable were also recorded. Results: Ten patients (four men and six women) with a mean age of 36.5 years (range = 26–45) were included. Reasons for cariprazine initiation included inadequate treatment response, persistent negative symptoms and/or tolerability issues with clozapine or previous augmentation options. Two patients discontinued cariprazine within the first 6 weeks due to restlessness and poor response, respectively. There was a significant reduction in the median total PANSS score from baseline to 3 months (from 59 to 22.5, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|